BioGenerator

Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, focused on enhancing clinical practice through innovative software solutions. Founded in 2017 as a spin-off from Washington University, SentiAR is developing a 3D visualization platform that utilizes real-time holography to display a patient's anatomy and catheter location during interventional procedures. This technology aims to improve the speed and safety of care delivery by enabling clinicians to visualize critical information "floating" above the patient, allowing for hands-free control. The platform is particularly designed for the treatment and analysis of cardiac arrhythmias in catheter lab environments. SentiAR is working towards obtaining FDA approval for its software, which has the potential to transform the experience for both clinicians and patients in medical settings.

Omniose, formerly known as VaxNewMo LLC, is a biotechnological company based in St. Louis, Missouri, focused on the development of next-generation conjugate vaccines targeting infectious diseases. Founded in 2016, the company utilizes proprietary in vivo conjugating technology to create innovative vaccine solutions. By advancing its research in conjugate vaccines, Omniose aims to address significant health challenges posed by infectious pathogens, contributing to global public health efforts.

Cadre Bioscience, LLC develops therapeutics for human diseases. The company was founded in 2019 and is based in Saint Louis, Missouri.

Healthy Bytes, Inc. develops a software for personalized and expert nutritional counseling. It offers Healthy Bytes, a platform that connects physicians, employers, and patients to nutritional counseling. The company’s platform also helps users to book their private consultation, and consult registered dietitian online. Healthy Bytes, Inc. was founded in 2014 and is headquartered in Saint Louis, Missouri with an additional office in New York, New York.

Readout is a digital health company with a mission to help patients better manage their own health by providing novel, clinically-backed tools to easily measure health biomarkers. Biosense was launched in early 2020 as a Class 1 medical device in the clinical, consumer, and research market after a successful clinical trial. As the only clinically-backed breath ketone measurement handheld device+app, Biosense provides full-day feedback of ketosis with unlimited measurements leading to protocol adherence and better outcomes. Biosense is used by obesity and diabetes clinics for in-home testing of ketosis, pharma and academic trials, as well as DTC via https://mybiosense.com.

Aggio, LLC is an information technology company that specializes in developing cloud-based sales applications tailored for the agriculture industry. Established in 2016 and headquartered in St. Louis, Missouri, with an additional location in Madison, New Jersey, Aggio offers a platform designed to enhance marketing and sales processes. Its solutions facilitate data-driven decision-making through advanced analytics, data harmonization, and visualization, enabling clients to effectively engage their customers and channel partners.

BacterioScan, Inc., a medical device company, designs products to diagnose and treat infectious diseases. The company offers 216Dx UTI System for detecting bacteria indicative of a urinary tract infection (UTI) in clinical urine samples, as well as identifying appropriate antibiotic treatment. Its product pipeline also includes 216R Antibiotic Susceptibility Testing System that detects bacterial infection, determines its resistance to a range of antibiotics, and provides clinicians with patient-specific antimicrobial resistance profiles. The company was incorporated in 2008 and is based in St Louis, Missouri.

Arch Innotek, LLC, a biotech company, engages in engineering microorganisms to produce natural ingredients that are beneficial to human and animal health. It focuses on the development of high-value molecules for food, feed, pharmaceutical, and cosmetics industries. The company also provides HPLC analysis, LC-MS analysis, protein purification, fermentation for strain optimization, and vector construction for protein expression and molecular cloning. Arch Innotek, LLC was incorporated in 2013 and is based in St. Louis, Missouri.

Start Right commercializes convenient, protein-packed, nutritional breakfast foods.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

Kalocyte is a pre-clinical stage healthcare biotech startup company that provides artificial red blood cell substitutes used for trauma care related services. The company develops a demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable, or in short supply. Kalocyte was founded in 2016 and is headquartered in Baltimore, Maryland.

Omniose, formerly known as VaxNewMo LLC, is a biotechnological company based in St. Louis, Missouri, focused on the development of next-generation conjugate vaccines targeting infectious diseases. Founded in 2016, the company utilizes proprietary in vivo conjugating technology to create innovative vaccine solutions. By advancing its research in conjugate vaccines, Omniose aims to address significant health challenges posed by infectious pathogens, contributing to global public health efforts.

Canopy Biosciences is a biotechnology company based in St. Louis, Missouri, founded in 2016. It specializes in providing research tools and services for genetic engineering and personalized medicine. The company's gene editing technology, known as TUNR, works by targeting translation elongation to insert polyA tracks into specific coding regions of the genome. This process effectively reduces the levels of mRNA transcribed from the gene, leading to a suppression of protein expression. The technology was initially developed by Professors Sergej Djuranovic and Rachel Green at Washington University School of Medicine and Johns Hopkins University, respectively. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Atomation, founded in Tel Aviv and now with headquarters in Saint Louis, Missouri, is a business-to-business solutions company that uses an innovative Internet of Things (IoT) platform to connect existing, in-field, legacy objects and assets to the internet. Focused on making the data gathered by sensors into useful and actionable information, Atomation solves problems differently with affordable and simple solutions that allow businesses to transform operations and optimize their bottom line.

Plastomics Inc. is a biotechnology company based in Saint Louis, Missouri, that specializes in chloroplast genetic engineering to enhance crop performance. Founded in 2016, the company focuses on developing advanced crops through gene stacking and rapid breeding techniques, aimed at improving yield production and nutritional quality. Plastomics' technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, which helps seed companies create more effective biotech crops. This innovative approach not only eliminates cross-pollination but also enables unique maternal inheritance, thereby reducing both breeding timelines and costs associated with bringing new products to market. Through its efforts, Plastomics addresses various challenges faced by the agricultural industry.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, focused on enhancing clinical practice through innovative software solutions. Founded in 2017 as a spin-off from Washington University, SentiAR is developing a 3D visualization platform that utilizes real-time holography to display a patient's anatomy and catheter location during interventional procedures. This technology aims to improve the speed and safety of care delivery by enabling clinicians to visualize critical information "floating" above the patient, allowing for hands-free control. The platform is particularly designed for the treatment and analysis of cardiac arrhythmias in catheter lab environments. SentiAR is working towards obtaining FDA approval for its software, which has the potential to transform the experience for both clinicians and patients in medical settings.

CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

Medaware Solutions, Inc. provides a platform to connect healthcare teams. It offers mViva, a platform that enables payers and providers to engage with patients and their relatives throughout the continuum of care. The company’s platform also enables multi-disciplinary teams to interact in patient-centric threads for coordination of care, as well as allows patients and care teams to capture and share data through a secure HIPAA-compliant platform. Medaware Solutions, Inc. was incorporated in 2014 and is based in St. Louis, Missouri.

Accuronix Therapeutics, Inc. develops oncology therapies for pancreatic cancer. The company was founded in 2015 and is based in the United States.

Edison Agrosciences, Inc., an agricultural biotechnology company, develops biotechnological solutions for the development of plant-based industrial materials in United States. It primarily focuses on the development of alternative rubber crops for the manufacture of consumer, medical, and industrial products. The company was incorporated in 2013 and is based in Durham, North Carolina.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

Nitrogenics is a plant biotechnology company providing research analysis on nitrogen fixation in crop plants. Nitrogenics' services include data related to plant enzymes that are inserted in the genome of tobacco, enabling researchers to get to research on plants that absorbs nitrogen directly from the atmosphere, rather than from fertilized soil.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MedSocket of Missouri, Inc. provides health information technology solutions. It offers 1-CDS (1-Click Decision Support), a clinical decision support system; and 1-Search, a search engine that provides evidence-based information for clinicians. The company was founded in 2012 and is based in Columbia, Missouri.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

Cofactor Genomics is a Predictive Immune Modeling company driven to remove the barriers that have prohibited the advancement of true precision medicine. Cofactor is enabling the industry to move beyond isolated, single-analyte biomarkers to powerful multidimensional biomarkers using Health Expression Models. Through their molecular, informatic, and database tools, and one of the first CAP-certified, clinical RNA sequencing laboratories, Cofactor enables their partners to deliver more expedient, cost effective, and successful clinical trials.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

GeneriCo, LLC is a pharmaceutical company established in 2013 and based in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea. The company specializes in developing and marketing generic pharmaceuticals, particularly in therapeutic areas such as cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo focuses on niche markets that have been overlooked by larger generic pharmaceutical companies, often involving technically challenging formulations and innovative drug delivery technologies. This unique approach allows GeneriCo to target opportunities that are not appealing to mid and large competitors, while also being too complex for smaller firms. The company serves a global customer base, providing essential medications to meet diverse health needs.

NeuroLutions Inc. is a company based in St. Louis, Missouri, that specializes in developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled by neurological injuries. Founded in 2007, the company focuses on creating non-invasive neurorehabilitation devices that assist stroke survivors in regaining lost arm function. Utilizing non-invasive electroencephalography (EEG) electrodes, NeuroLutions' technology captures brain activity without the need for implanted electrodes. This EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. The devices facilitate muscle re-education and help maintain or enhance the range of motion, offering a promising avenue for rehabilitation in individuals affected by neurological conditions.

CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

RNAgri, founded in 2011 and based in St. Louis, Missouri, specializes in the development and commercialization of ribonucleic acid (RNA) technologies. The company focuses on creating innovative solutions that facilitate the mass production of exogenous RNA interference (RNAi)-based products through large-scale fermentation processes. This technology is designed to enhance agricultural practices by enabling farmers to protect and improve their crops and livestock. By addressing key challenges in RNA production, RNAgri aims to contribute to advancements in sustainable agriculture.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

YourBevCo, LLC is a beverage device company developing a pipeline of innovative, disruptive consumer devices that safely and effectively remove problematic ingredients from beverages that are known to cause allergic or sensitivity reactions.

ImmunoPhotonics, Inc. operates as a biotechnology company that engages in the development of a proprietary novel drug product for use in an in situ autologous cancer vaccine for the treatment of metastatic solid tumor cancers. The company was founded in 2008 and is based in St. Louis, Missouri.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Prostate Management Diagnostics creates tests and develops a fluid-based screening tool. It specializes in the fields of health diagnostics, medical, and healthcare. It was founded in 2014 and headquartered in San Francisco, California.

MedSocket of Missouri, Inc. provides health information technology solutions. It offers 1-CDS (1-Click Decision Support), a clinical decision support system; and 1-Search, a search engine that provides evidence-based information for clinicians. The company was founded in 2012 and is based in Columbia, Missouri.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

ImmunoPhotonics, Inc. operates as a biotechnology company that engages in the development of a proprietary novel drug product for use in an in situ autologous cancer vaccine for the treatment of metastatic solid tumor cancers. The company was founded in 2008 and is based in St. Louis, Missouri.

Confluence gathers, filters, combines and presents the pharmaceutical intelligence you need. It turns manual into automatic, risk into reliability and wait into wow. With Confluence you start where it counts: crucial planning and decision-making. Skip the assembly, start with Confluence.

Benson Hill is an agricultural technology company focused on crop improvement, particularly in soy protein innovation. By leveraging its proprietary CropOS™ platform, the company integrates machine learning, genomic data, and traditional breeding techniques to streamline the development of healthier and more sustainable food products. Benson Hill emphasizes unlocking the natural genetic diversity of plants to empower innovators in creating flavorful and nutritious ingredients. The company operates a Crop Accelerator for rapid prototyping and is developing a diverse seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. Its revenue is generated from both proprietary and non-proprietary product categories, reflecting its commitment to advancing agricultural innovation.

Tansna Therapeutics, Inc., a drug discovery and development company, develops and commercializes oral drugs to treat epilepsy. The company focuses on novel therapies for the treatment of central nervous system disorders. Its products under pipeline include oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy. The company was founded in 2010 and is based in St. Louis, Missouri.

BacterioScan, Inc., a medical device company, designs products to diagnose and treat infectious diseases. The company offers 216Dx UTI System for detecting bacteria indicative of a urinary tract infection (UTI) in clinical urine samples, as well as identifying appropriate antibiotic treatment. Its product pipeline also includes 216R Antibiotic Susceptibility Testing System that detects bacterial infection, determines its resistance to a range of antibiotics, and provides clinicians with patient-specific antimicrobial resistance profiles. The company was incorporated in 2008 and is based in St Louis, Missouri.

Graematter, Inc. specializes in regulatory intelligence solutions, offering a comprehensive platform that allows regulatory professionals to efficiently locate, analyze, and track essential regulatory information. The SOFIE Regulatory Intelligence System integrates data from various authoritative sources, including the Department of Health and Human Services, the Food and Drug Administration, and other regulatory bodies, facilitating monitoring of the regulatory landscape for aspects such as inspections, sanctions, and adverse events. The platform features tools such as Fast Search for broad queries, Advanced Search for detailed investigations, Regulatory Surveillance for new documents, and Trend Analysis to track key indicators. Additionally, Graematter provides research and regulatory consulting services to enhance clients' understanding and navigation of complex regulatory environments. Founded in 2012 and based in St. Louis, Missouri, the company has evolved its solutions since the initial concept was developed in 1999, continuously adapting to the growing volume and complexity of regulatory information.

GeneriCo, LLC is a pharmaceutical company established in 2013 and based in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea. The company specializes in developing and marketing generic pharmaceuticals, particularly in therapeutic areas such as cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo focuses on niche markets that have been overlooked by larger generic pharmaceutical companies, often involving technically challenging formulations and innovative drug delivery technologies. This unique approach allows GeneriCo to target opportunities that are not appealing to mid and large competitors, while also being too complex for smaller firms. The company serves a global customer base, providing essential medications to meet diverse health needs.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MediBeacon Inc. specializes in real-time kidney function monitoring solutions, focusing on advancing nephrology through innovative optical diagnostic technology. The company has developed the NIC-Kidney device, which enables monitoring of the glomerular filtration rate in preclinical settings, and the MediBeacon renal function system, which utilizes an optical skin sensor along with a proprietary agent that illuminates under light. This system allows for continuous real-time monitoring of kidney function, providing clinicians with critical data to enhance patient care. Additionally, MediBeacon's product pipeline includes a range of light-activated agents designed for physiological monitoring and surgical guidance. Founded in 2012 and headquartered in St. Louis, Missouri, MediBeacon aims to improve patient outcomes in intensive care units and operating rooms through its innovative approaches to organ function measurement and management.

Tansna Therapeutics, Inc., a drug discovery and development company, develops and commercializes oral drugs to treat epilepsy. The company focuses on novel therapies for the treatment of central nervous system disorders. Its products under pipeline include oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy. The company was founded in 2010 and is based in St. Louis, Missouri.

Benson Hill is an agricultural technology company focused on crop improvement, particularly in soy protein innovation. By leveraging its proprietary CropOS™ platform, the company integrates machine learning, genomic data, and traditional breeding techniques to streamline the development of healthier and more sustainable food products. Benson Hill emphasizes unlocking the natural genetic diversity of plants to empower innovators in creating flavorful and nutritious ingredients. The company operates a Crop Accelerator for rapid prototyping and is developing a diverse seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. Its revenue is generated from both proprietary and non-proprietary product categories, reflecting its commitment to advancing agricultural innovation.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

Apertus Pharmaceuticals is an Active Pharmaceutical Ingredient, or API, manufacturing company targeting dosage form manufacturing companies within the pharmaceutical industry. Apertus Pharmaceuticals provides controlled substance APIs, non controlled substance APIs, and intellectual property to the pharmaceutical market. In addition, Apertus Pharmaceuticals utilizes the philosophies of Green Chemistry as outlined by the FDA and will target higher purity standards than those set by the current standard setting authorities. Apertus is led by CEO Rick Ryan, Ph.D. and CSO David Gindelberger, Ph.D.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Companion Pharma is an animal health product development company that will develop innovative new formulations of drugs for use under prescription in companion animals. Companion will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration and are available in doses that meet the needs of the highly variable weight profile of companion animal pets.

RNAgri, founded in 2011 and based in St. Louis, Missouri, specializes in the development and commercialization of ribonucleic acid (RNA) technologies. The company focuses on creating innovative solutions that facilitate the mass production of exogenous RNA interference (RNAi)-based products through large-scale fermentation processes. This technology is designed to enhance agricultural practices by enabling farmers to protect and improve their crops and livestock. By addressing key challenges in RNA production, RNAgri aims to contribute to advancements in sustainable agriculture.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.

Mobius Therapeutics, LLC develops sterile injectable pharmaceutical products for ophthalmic applications in the United States. It offers Mitosol (mitomycin for solution) kit, an ophthalmic formulation of MMC that contains a closed-system transfer device and sponge tray enabling the safe reconstitution and transfer of MMC; and Amphadase, a hyaluronidase injection. The company serves ophthalmologists and their patients. It offers its products online. Mobius Therapeutics, LLC was founded in 2006 and is based in St Louis, Missouri.

Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.

Confluence Discovery Technologies is a drug discovery contract research organization (CRO) providing a variety of technical services including mechanistic enzymology, target validation and characterization, screening and assay development, biomarker development and measurement. The company offers its customers novel approaches to identification of kinase inhibitors along with decades of experience developing clinical candidates for this class. Founders were key scientific leaders in Pfizer's Inflammation Research Unit. Confluence is located at the BioGenerator Accelerator Labs.

As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

PixelEXX Systems Inc. develops prototype imaging devices for diagnosing cancer. The products include nanoarrays that take images of molecular signals associated with cellular activity. PixelEXX Systems Inc. was founded in 2008 and is based in Saint Louis, Missouri.

APT Therapeutics is a biotechnology company based in St. Louis, Missouri, focused on developing innovative antiplatelet therapies. The company aims to transform human apyrase into a life-saving medicine through advanced techniques in protein engineering, protein informatics, and cheminformatics software. APT Therapeutics' therapies target critical medical conditions such as acute myocardial infarction, stroke, and complications arising from transplantation. By enhancing the effectiveness of these treatments, the company seeks to minimize damage to patients during heart attacks and improve their overall outcomes.